hongxin zhang

Dr. hongxin zhang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cancer Letters
Verified
Journal Article
Closed access
PYPeng Yuan
Peng Yuan
TYTao Yang
Tao Yang
JMJiao Mu
Jiao Mu
JZJing Zhao
Jing Zhao
YYYi Yang
Yi Yang
JLJibin Li
Jibin Li

23 March 2017 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PYPeng Yuan
Peng Yuan
JLJibin Li
Jibin Li
FZFeng Zhou
Feng Zhou
QHQichao Huang
Qichao Huang
JZJiansheng Zhang
Jiansheng Zhang
JXJinliang Xing
Jinliang Xing
Emerging evidences show that disruption of the circadian rhythm is associated with tumor initiation and progression. Neuronal PAS domain protein 2 (NPAS2), one of the core circadian molecules, has been proved to be a potential prognostic biomarker in colorectal and breast cancers. However, to date, the potential functional roles and molecular mechanisms by which NPAS2 affects cancer cell survival are greatly unclear, especially in hepatocellular carcinoma (HCC). We first investigated the expression of NPAS2 and its clinical significance in HCC. We then systematically explored the role of NPAS2 in HCC cell survival both in vitro and in vivo and the underlying mechanism. NPAS2 was frequently upregulated in HCC, which significantly facilitated cell survival both in vitro and in vivo mainly by promoting cell proliferation and inhibiting mitochondria-dependent intrinsic apoptosis, and thus contributed to poor prognosis of HCC patients. Mechanistically, the survival-promoting role of NPAS2 was mediated by transcriptional upregulation of the CDC25A phosphatase and subsequent dephosphorylation of CDK2/4/6 and Bcl-2, which induced cell proliferation and inhibited cell apoptosis in HCC, respectively. Moreover, BMAL1, another core clock transcription factor, was identified to heterodimerize with NPAS2 to bind to the E-box element in the promoter of CDC25A and be associated with the NPAS2-mediated tumor cell survival in HCC. Our findings demonstrate that NPAS2 has a critical role in HCC cell survival and tumor growth, which is mainly mediated by transcriptional upregulation of CDC25A. Thereby, NPAS2 may serve as a potential therapeutic target in HCC patients.

10 April 2015 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
KQKai Qu
Kai Qu
ZYZhaoyong Yan
Zhaoyong Yan
YWYousheng Wu
Yousheng Wu
YCYibing Chen
Yibing Chen
PQPing Qu
Ping Qu
JZJing Zhang
Jing Zhang

12 June 2023 in Metabolism
Verified
Journal Article
Closed access
TYTao Yang
Tao Yang
NLNing Liang
Ning Liang
JZJiahao Zhang
Jiahao Zhang
YBYaxing Bai
Yaxing Bai
YLYuedan Li
Yuedan Li
HZhongxin zhang
hongxin zhang

1 January 2022 in International Journal of Biological Sciences
Verified
Journal Article
Open access
JLJing Li
Jing Li
TYTao Yang
Tao Yang
QWQihong Wang
Qihong Wang
YLYuedan Li
Yuedan Li
HWHaiyan Wu
Haiyan Wu
JLJin-Feng Li
Jin-Feng Li
Recently, increasing attention has been paid to the role of Squalene epoxidase (SQLE) in several types of cancers. However, its functional role in tumor progression of head and neck squamous cell carcinoma (HNSCC) is still unclear. We performed bioinformatic analyses and relative experiments to assess the potential mechanism of SQLE-mediated HNSCC malignancy. And the results showed that SQLE was significantly upregulated in tumor samples compared with peritumor samples. Mechanistically, miR-584-5p downregulation may lead to the upregulation of SQLE in HNSCC. Moreover, high SQLE expression in HNSCC was associated with TNM stage, distant metastasis, and poor survival, indicating that SQLE be involved in the progression of HNSCC. Furtherly, SQLE boosted proliferation, migration, invasion of HNSCC cells in vitro and in vivo. Bioinformatic studies showed that PI3K/Akt signaling participated in HNSCC progression mediated by SQLE overexpression, which is confirmed by in vitro and in vivo analysis. Particularly, treatment with terbinafine, an inhibitor of SQLE widely used in the treatment of fungal infections, showed a therapeutic influence on HNSCC. Our findings demonstrate that SQLE plays a vital role in HNSCC progression, providing research evidence for SQLE as a prospective HNSCC therapeutic target and for terbinafine as a candidate drug of HNSCC treatment in the future

18 June 2014 in Cancer Science
Verified
Journal Article
Open access
PDF file
PYPeng Yuan
Peng Yuan
SWShen Wang
Shen Wang
FZFeng Zhou
Feng Zhou
SWShaogui Wan
Shaogui Wan
YYYefa Yang
Yefa Yang
JXJinliang Xing
Jinliang Xing
The functional abnormality of circadian regulation genes is involved in the development and progression of hepatocellular carcinoma (HCC). However, the association between functional single nucleotide polymorphisms (SNPs) in circadian gene NPAS2 and the overall survival of HCC patients treated with transcatheter arterial chemoembolization (TACE) has never been investigated. Six functional SNPs in the NPAS2 gene were genotyped using the Sequenom iPLEX genotyping system in a cohort of 448 unresectable Chinese patients with HCC treated with TACE. Multivariate Cox proportional hazards model and Kaplan–Meier curves were used for the prognosis analysis. We found that two SNPs, rs1053096 and rs2305160, in the NPAS2 gene showed significant associations with overall death risk in HCC patients in the recessive model (hazard ratio [HR] = 1.48; 95% confidence interval [CI], 1.13–1.94; P = 0.004) and in the dominant model (HR = 1.63; 95% CI, 1.29–2.07; P < 0.001), respectively. Moreover, we observed a cumulative effect of these two SNPs on HCC overall survival, indicating a significant trend of increasing death risk with increasing number of unfavorable genotypes (P for trend < 0.001). Compared with the patients without any unfavorable genotypes, the HRs for patients with one and two unfavorable genotypes were 1.41 (95% CI, 1.10–1.82; P = 0.007) and 2.09 (95% CI, 1.46–2.97, P < 0.001), respectively. The haplotype and diplotype analyses further characterized the association between NPAS2 genotype and survival of HCC patients. Our results for the first time suggest that NPAS2 gene polymorphisms may serve as an independent prognostic marker for HCC patients treated with TACE.